Key points are not available for this paper at this time.
Key Points Selinexor is an oral XPO1 inhibitor with antimyeloma activity. The RP2D is 45 mg/m2 (80 mg) selinexor plus 20 mg dexamethasone given twice weekly.
Chen et al. (Mon,) studied this question.